Johnson & Johnson prepares $2.58 billion option to acquire Sail Biomedicines, expanding in-vivo CAR-T portfolio

Johnson & Johnson announced a $2.58 billion option agreement to purchase Sail Biomedicines, a Flagship Pioneering‑backed biotech focused on in‑vivo CAR‑T therapies.

The deal includes an upfront payment of $785 million, giving J&J immediate access to Sail’s platform while the full acquisition terms remain conditional.

The move signals J&J’s intent to deepen its presence in the rapidly evolving in‑vivo CAR‑T market, where competition among major cell‑therapy players is intensifying.

Analysts view the partnership as a strategic effort to broaden J&J’s cell‑therapy pipeline and potentially accelerate the development of next‑generation cancer treatments.